The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Association Between Sustained Virological Response and All-Cause Mortality Among Patients With Chronic Hepatitis C and Advanced Hepatic Fibrosis
Open accessAbstract
CONTEXT: Chronic hepatitis C virus (HCV) infection outcomes include liver failure, hepatocellular carcinoma (HCC), and liver-related death. OBJECTIVE: To assess the association between sustained virological response (SVR) and all-cause mortality in patients with chronic HCV infection and advanced hepatic fibrosis. DESIGN, SETTING, AND PATIENTS: An international, multicenter, long-term follow-up study from 5 large tertiary care hospitals in Europe and Canada of 530 patients with chronic HCV infection who started an interferon-based treatment regimen between 1990 and 2003, following histological proof of advanced hepatic fibrosis or cirrhosis (Ishak score 4-6). Complete follow-up ranged between January 2010 and October 2011. MAIN OUTCOME MEASURES: All-cause mortality. Secondary outcomes were liver failure, HCC, and liver-related mortality or liver transplantation. RESULTS: The 530 study patients were followed up for a median (interquartile range [IQR]) of 8.4 (6.4-11.4) years. The baseline median (IQR) age was 48 (42-56) years and 369 patients (70%) were men. The Ishak fibrosis score was 4 in 143 patients (27%), 5 in 101 patients (19%), and 6 in 286 patients (54%). There were 192 patients (36%) who achieved SVR; 13 patients with SVR and 100 without SVR died (10-year cumulative all-cause mortality rate, 8.9% [95% CI, 3.3%-14.5%] with SVR and 26.0% [95% CI, 20.2%-28.4%] without SVR; P < .001). In time-dependent multivariate Cox regression analysis, SVR was associated with reduced risk of all-cause mortality (hazard ratio [HR], 0.26; 95% CI, 0.14-0.49; P < .001) and reduced risk of liver-related mortality or transplantation (HR, 0.06; 95% CI, 0.02-0.19; P < .001), the latter occurring in 3 patients with SVR and 103 without SVR. The 10-year cumulative incidence rate of liver-related mortality or transplantation was 1.9% (95% CI, 0.0%-4.1%) with SVR and 27.4% (95% CI, 22.0%-32.8%) without SVR (P < .001). There were 7 patients with SVR and 76 without SVR who developed HCC (10-year cumulative incidence rate, 5.1%; 95% CI, 1.3%-8.9%; vs 21.8%; 95% CI, 16.6%-27.0%; P < .001), and 4 patients with SVR and 111 without SVR experienced liver failure (10-year cumulative incidence rate, 2.1%; 95% CI, 0.0%-4.5%; vs 29.9%; 95% CI, 24.3%-35.5%; P < .001). CONCLUSION: Among patients with chronic HCV infection and advanced hepatic fibrosis, sustained virological response to interferon-based treatment was associated with lower all-cause mortality.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Statistical Analysis With Missing Data
Lahiff, M., Little, R. J. A., & Rubin, D. B. (1989) · Journal of the American Statistical Association · doi:10.2307/2289883 · Cited by 17,265
Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus Infection
Fried, M. W., Shiffman, M. L., Reddy, K. R., Smith, C., Marinos, G., Gonçales, F. L., Häussinger, D., Diago, M., Carosi, G., Dhumeaux, D., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020047 · Cited by 6,389
Manns, M. P., McHutchison, J. G., Gordon, S. C., Rustgi, V. K., Shiffman, M., Reindollar, R., Goodman, Z. D., Koury, K., Ling, M.-H., & Albrecht, J. K. (2001) · The Lancet · doi:10.1016/s0140-6736(01)06102-5 · Cited by 6,029
Self-citationManagement of Hepatocellular Carcinoma *
Bruix, J., & Sherman, M. (2005) · Hepatology · doi:10.1002/hep.20933 · Cited by 5,857
Histological grading and staging of chronic hepatitis
Ishak, K., Baptista, A., Bianchi, L., Callea, F., De Groote, J., Gudat, F., Denk, H., Desmet, V., Korb, G., MacSween, R. N. M., et al. (1995) · Journal of Hepatology · doi:10.1016/0168-8278(95)80226-6 · Cited by 5,029
Hadziyannis, S. J., Sette, H., Morgan, T. R., Balan, V., Diago, M., Marcellin, P., Ramadori, G., Bodenheimer, H., Bernstein, D., Rizzetto, M., et al. (2004) · Annals of Internal Medicine · doi:10.7326/0003-4819-140-5-200403020-00010 · Cited by 2,836
Self-citationBoceprevir for Untreated Chronic HCV Genotype 1 Infection
Poordad, F., McCone, J., Bacon, B. R., Bruno, S., Manns, M. P., Sulkowski, M. S., Jacobson, I. M., Reddy, K. R., Goodman, Z. D., Boparai, N., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1010494 · Cited by 2,520
Self-citationTelaprevir for Previously Untreated Chronic Hepatitis C Virus Infection
Jacobson, I. M., McHutchison, J. G., Dusheiko, G., Di Bisceglie, A. M., Reddy, K. R., Bzowej, N. H., Marcellin, P., Muir, A. J., Ferenci, P., Flisiak, R., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1012912 · Cited by 2,398
Self-citationTreatment of Chronic Hepatitis C with Recombinant Interferon Alfa
Davis, G. L., Balart, L. A., Schiff, E. R., Lindsay, K., Bodenheimer, H. C., Perrillo, R. P., Carey, W., Jacobson, I. M., Payne, J., Dienstag, J. L., et al. (1989) · New England Journal of Medicine · doi:10.1056/nejm198911303212203 · Cited by 1,633
Recombinant Interferon Alfa Therapy for Chronic Hepatitis C
Di Bisceglie, A. M., Martin, P., Kassianides, C., Lisker-Melman, M., Murray, L., Waggoner, J., Goodman, Z., Banks, S. M., & Hoofnagle, J. H. (1989) · New England Journal of Medicine · doi:10.1056/nejm198911303212204 · Cited by 1,212
Cited by
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
Galle, P. R., Forner, A., Llovet, J. M., Mazzaferro, V., Piscaglia, F., Raoul, J.-L., Schirmacher, P., & Vilgrain, V. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.03.019 · Cited by 11,406
The HCV Life Cycle: In vitro Tissue Culture Systems and Therapeutic Targets
Gerold, G., & Pietschmann, T. (2014) · Digestive Diseases · doi:10.1159/000360830 · Cited by 4,854
A global view of hepatocellular carcinoma: trends, risk, prevention and management
Yang, J. D., Hainaut, P., Gores, G. J., Amadou, A., Plymoth, A., & Roberts, L. R. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0186-y · Cited by 4,228
EASL Recommendations on Treatment of Hepatitis C 2018
Pawlotsky, J.-M., Negro, F., Aghemo, A., Berenguer, M., Dalgard, O., Dusheiko, G., Marra, F., Puoti, M., & Wedemeyer, H. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.03.026 · Cited by 2,827
Self-citationLlovet, J. M., Zucman-Rossi, J., Pikarsky, E., Sangro, B., Schwartz, M., Sherman, M., & Gores, G. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.18 · Cited by 2,531
Treatment of HCV Infection by Targeting MicroRNA
Janssen, H. L. A., Reesink, H. W., Lawitz, E. J., Zeuzem, S., Rodriguez-Torres, M., Patel, K., van der Meer, A. J., Patick, A. K., Chen, A., Zhou, Y., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1209026 · Cited by 2,204
Self-citationPanel, A. H. G. (2015) · Hepatology · doi:10.1002/hep.27950 · Cited by 1,382
EASL recommendations on treatment of hepatitis C: Final update of the series☆
Pawlotsky, J.-M., Negro, F., Aghemo, A., Berenguer, M., Dalgard, O., Dusheiko, G., Marra, F., Puoti, M., & Wedemeyer, H. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.08.018 · Cited by 1,252
Self-citationEASL Recommendations on Treatment of Hepatitis C 2015
(2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.03.025 · Cited by 1,156
EASL Recommendations on Treatment of Hepatitis C 2016
(2017) · Journal of Hepatology · doi:10.1016/j.jhep.2016.09.001 · Cited by 985
Ghany, M. G., Morgan, T. R., & Panel, A. H. C. G. (2020) · Hepatology · doi:10.1002/hep.31060 · Cited by 955
Ryerson, A. B., Eheman, C. R., Altekruse, S. F., Ward, J. W., Jemal, A., Sherman, R. L., Henley, S. J., Holtzman, D., Lake, A., Noone, A., et al. (2016) · Cancer · doi:10.1002/cncr.29936 · Cited by 945
Treatment of HCV with ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin
Feld, J. J., Kowdley, K. V., Coakley, E., Sigal, S., Nelson, D. R., Crawford, D., Weiland, O., Aguilar, H., Xiong, J., Pilot-Matias, T., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1315722 · Cited by 903
Self-citationPathobiology of liver fibrosis: a translational success story
Lee, Y. A., Wallace, M. C., & Friedman, S. L. (2015) · Gut · doi:10.1136/gutjnl-2014-306842 · Cited by 894
ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin for Hepatitis C with Cirrhosis
Poordad, F., Hezode, C., Trinh, R., Kowdley, K. V., Zeuzem, S., Agarwal, K., Shiffman, M. L., Wedemeyer, H., Berg, T., Yoshida, E. M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402869 · Cited by 874
Self-citationEASL Clinical Practice Guidelines: Management of hepatitis C virus infection
(2014) · Journal of Hepatology · doi:10.1016/j.jhep.2013.11.003 · Cited by 855
Panel, A.-I. H. G., Chung, R. T., Ghany, M. G., Kim, A. Y., Marks, K. M., Naggie, S., Vargas, H. E., Aronsohn, A. I., Bhattacharya, D., Broder, T., et al. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/ciy585 · Cited by 717
Oral Direct-Acting Agent Therapy for Hepatitis C Virus Infection: A Systematic Review
Falade-Nwulia, O., Suarez-Cuervo, C., Nelson, D. R., Fried, M. W., Segal, J. B., & Sulkowski, M. S. (2017) · Annals of Internal Medicine · doi:10.7326/m16-2575 · Cited by 688
Carrat, F., Fontaine, H., Dorival, C., Simony, M., Diallo, A., Hezode, C., De Ledinghen, V., Larrey, D., Haour, G., Bronowicki, J.-P., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(18)32111-1 · Cited by 628
Understanding the hepatitis C virus life cycle paves the way for highly effective therapies
Scheel, T. K. H., & Rice, C. M. (2013) · Nature Medicine · doi:10.1038/nm.3248 · Cited by 554
Competing risks and prognostic stages of cirrhosis: a 25‐year inception cohort study of 494 patients
D'Amico, G., Pasta, L., Morabito, A., D'Amico, M., Caltagirone, M., Malizia, G., Tinè, F., Giannuoli, G., Traina, M., Vizzini, G., et al. (2014) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12721 · Cited by 547
Nahon, P., Bourcier, V., Layese, R., Audureau, E., Cagnot, C., Marcellin, P., Guyader, D., Fontaine, H., Larrey, D., De Lédinghen, V., et al. (2017) · Gastroenterology · doi:10.1053/j.gastro.2016.09.009 · Cited by 538
Retreatment of HCV with ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin
Zeuzem, S., Jacobson, I. M., Baykal, T., Marinho, R. T., Poordad, F., Bourlière, M., Sulkowski, M. S., Wedemeyer, H., Tam, E., Desmond, P., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1401561 · Cited by 517
Self-citationManns, M. P., Buti, M., Gane, E., Pawlotsky, J.-M., Razavi, H., Terrault, N., & Younossi, Z. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.6 · Cited by 506
Self-citationFoster, G. R., Irving, W. L., Cheung, M. C. M., Walker, A. J., Hudson, B. E., Verma, S., McLauchlan, J., Mutimer, D. J., Brown, A., Gelson, W. T. H., et al. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.01.029 · Cited by 492
Moyer, V. A. (2013) · Annals of Internal Medicine · doi:10.7326/0003-4819-159-5-201309030-00672 · Cited by 475
Beste, L. A., Leipertz, S. L., Green, P. K., Dominitz, J. A., Ross, D., & Ioannou, G. N. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.07.056 · Cited by 459
Manns, M., Samuel, D., Gane, E. J., Mutimer, D., McCaughan, G., Buti, M., Prieto, M., Calleja, J. L., Peck-Radosavljevic, M., Müllhaupt, B., et al. (2016) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(16)00052-9 · Cited by 451
Self-citationWebster, D. P., Klenerman, P., & Dusheiko, G. M. (2015) · The Lancet · doi:10.1016/s0140-6736(14)62401-6 · Cited by 439
Evidence-based clinical practice guidelines for Liver Cirrhosis 2020
Yoshiji, H., Nagoshi, S., Akahane, T., Asaoka, Y., Ueno, Y., Ogawa, K., Kawaguchi, T., Kurosaki, M., Sakaida, I., Shimizu, M., et al. (2021) · Journal of Gastroenterology · doi:10.1007/s00535-021-01788-x · Cited by 422
Cheung, M. C. M., Walker, A. J., Hudson, B. E., Verma, S., McLauchlan, J., Mutimer, D. J., Brown, A., Gelson, W. T. H., MacDonald, D. C., Agarwal, K., et al. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.06.019 · Cited by 408
Barua, S., Greenwald, R., Grebely, J., Dore, G. J., Swan, T., & Taylor, L. E. (2015) · Annals of Internal Medicine · doi:10.7326/m15-0406 · Cited by 401
“Regimens for treating HCV seem to be curative and reduce liver-related and all-cause mortality (5).”
BackgroundDiagnosis and Management of Cirrhosis and Its Complications: A Review
Tapper, E. B., & Parikh, N. D. (2023) · JAMA · doi:10.1001/jama.2023.5997 · Cited by 392
Global epidemiology and burden of HCV infection and HCV-related disease
Thrift, A. P., El-Serag, H. B., & Kanwal, F. (2017) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2016.176 · Cited by 382
Calvaruso, V., Cabibbo, G., Cacciola, I., Petta, S., Madonia, S., Bellia, A., Tinè, F., Distefano, M., Licata, A., Giannitrapani, L., et al. (2018) · Gastroenterology · doi:10.1053/j.gastro.2018.04.008 · Cited by 361
Extrahepatic Morbidity and Mortality of Chronic Hepatitis C
Negro, F., Forton, D., Craxì, A., Sulkowski, M. S., Feld, J. J., & Manns, M. P. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.08.035 · Cited by 361
Self-citationNonalcoholic steatohepatitis-related hepatocellular carcinoma: pathogenesis and treatment
Llovet, J. M., Willoughby, C. E., Singal, A. G., Greten, T. F., Heikenwälder, M., El-Serag, H. B., Finn, R. S., & Friedman, S. L. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-023-00754-7 · Cited by 354
Chhatwal, J., Kanwal, F., Roberts, M. S., & Dunn, M. A. (2015) · Annals of Internal Medicine · doi:10.7326/m14-1336 · Cited by 338
From non-A, non-B hepatitis to hepatitis C virus cure
Pawlotsky, J.-M., Feld, J. J., Zeuzem, S., & Hoofnagle, J. H. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.02.006 · Cited by 328
Self-citationGlobal Elimination of Chronic Hepatitis
Thomas, D. L. (2019) · New England Journal of Medicine · doi:10.1056/nejmra1810477 · Cited by 325
Kanwal, F., Kramer, J. R., Ilyas, J., Duan, Z., & El-Serag, H. B. (2014) · Hepatology · doi:10.1002/hep.27095 · Cited by 322
Late HDV RNA Relapse After Peginterferon Alpha-Based Therapy of Chronic Hepatitis Delta
Heidrich, B., Yurdaydın, C., Kabaçam, G., Ratsch, B. A., Zachou, K., Bremer, B., Dalekos, G. N., Erhardt, A., Tabak, F., Yalcin, K., et al. (2014) · Hepatology · doi:10.1002/hep.27102 · Cited by 301
Self-citationLawitz, E., Gane, E., Pearlman, B., Tam, E., Ghesquiere, W., Guyader, D., Alric, L., Bronowicki, J.-P., Lester, L., Sievert, W., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61795-5 · Cited by 299
Global control of hepatitis C: where challenge meets opportunity
Thomas, D. L. (2013) · Nature Medicine · doi:10.1038/nm.3184 · Cited by 280
Sulkowski, M., Hezode, C., Gerstoft, J., Vierling, J. M., Mallolas, J., Pol, S., Kugelmas, M., Murillo, A., Weis, N., Nahass, R., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61793-1 · Cited by 280
van der Meer, A. J., Feld, J. J., Hofer, H., Almasio, P. L., Calvaruso, V., Fernández-Rodríguez, C. M., Aleman, S., Ganne-Carrié, N., D’Ambrosio, R., Pol, S., et al. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2016.10.017 · Cited by 274
Self-citationvan der Ree, M. H., de Vree, J. M., Stelma, F., Willemse, S., van der Valk, M., Rietdijk, S., Molenkamp, R., Schinkel, J., van Nuenen, A. C., Beuers, U., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(16)31715-9 · Cited by 271
Lens, S., Alvarado-Tapias, E., Mariño, Z., Londoño, M.-C., LLop, E., Martinez, J., Fortea, J. I., Ibañez, L., Ariza, X., Baiges, A., et al. (2017) · Gastroenterology · doi:10.1053/j.gastro.2017.07.016 · Cited by 271
Comparison of hepatocellular carcinoma in Eastern versus Western populations
Choo, S. P., Tan, W. L., Goh, B. K. P., Tai, W. M., & Zhu, A. X. (2016) · Cancer · doi:10.1002/cncr.30237 · Cited by 264
Simmons, B., Saleem, J., Heath, K., Cooke, G. S., & Hill, A. (2015) · Clinical Infectious Diseases · doi:10.1093/cid/civ396 · Cited by 261
Kim, D., Li, A. A., Gadiparthi, C., Khan, M. A., Cholankeril, G., Glenn, J. S., & Ahmed, A. (2018) · Gastroenterology · doi:10.1053/j.gastro.2018.07.008 · Cited by 223
Kaplan, D. E., Serper, M. A., Mehta, R., Fox, R., John, B., Aytaman, A., Baytarian, M., Hunt, K., Albrecht, J., Njei, B., et al. (2019) · Gastroenterology · doi:10.1053/j.gastro.2019.01.026 · Cited by 145
Linas, B. P., Barter, D. M., Morgan, J. R., Pho, M. T., Leff, J. A., Schackman, B. R., Horsburgh, C. R., Assoumou, S. A., Salomon, J. A., Weinstein, M. C., et al. (2015) · Annals of Internal Medicine · doi:10.7326/m14-1313 · Cited by 101
“Cure, also known as sustained virologic response (SVR), is associated with a greatly reduced lifetime risk for liver-related morbidity and mortality and increased short-term survival for patients with advanced liver disease (4).”
Langhans, B., Nischalke, H. D., Krämer, B., Hausen, A., Dold, L., van Heteren, P., Hüneburg, R., Nattermann, J., Strassburg, C. P., & Spengler, U. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2016.12.019 · Cited by 96
LOXL2—A New Target in Antifibrogenic Therapy?
Puente, A., Fortea, J. I., Cabezas, J., Arias Loste, M. T., Iruzubieta, P., Llerena, S., Huelin, P., Fábrega, E., & Crespo, J. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20071634 · Cited by 79
Dieperink, E., Fuller, B., Isenhart, C., McMaken, K., Lenox, R., Pocha, C., Thuras, P., & Hauser, P. (2014) · Addiction · doi:10.1111/add.12679 · Cited by 45
Impact of treatment with direct-acting antivirals on anxiety and depression in chronic hepatitis C
Gallach, M., Vergara, M., da Costa, J. P., Miquel, M., Casas, M., Sanchez-Delgado, J., Dalmau, B., Rudi, N., Parra, I., Monllor, T., et al. (2018) · PLOS ONE · doi:10.1371/journal.pone.0208112 · Cited by 32
Arora, S. S., Axley, P., Ahmed, Z., Satapathy, S. K., Wong, R., Kuo, Y., & Singal, A. K. (2019) · Transplant International · doi:10.1111/tri.13424 · Cited by 24
Linas, B. P., Morgan, J. R., Pho, M. T., Leff, J. A., Schackman, B. R., Horsburgh, C. R., Assoumou, S. A., Salomon, J. A., Weinstein, M. C., Freedberg, K. A., et al. (2017) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofw266 · Cited by 19
Metadata
- Authors
- van der Meer, A. J., Veldt, B. J., Feld, J. J., Wedemeyer, H., Dufour, J.-F., Lammert, F., Duarte-Rojo, A., Heathcote, E. J., Manns, M. P., Kuske, L., Zeuzem, S., Hofmann, W. P., de Knegt, R. J., Hansen, B. E., & Janssen, H. L. A.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2012-12-26
- Volume
- 308
- Issue
- 24
- Pages
- 2584
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W1980154502
- Cited by
- 1,510
- References
- 25
- FWCI
- 72.81
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.